These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 39125777)
41. Orderly and nonstochastic acquisition of CD94/NKG2 receptors by developing NK cells derived from embryonic stem cells in vitro. Lian RH; Maeda M; Lohwasser S; Delcommenne M; Nakano T; Vance RE; Raulet DH; Takei F J Immunol; 2002 May; 168(10):4980-7. PubMed ID: 11994449 [TBL] [Abstract][Full Text] [Related]
42. Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy. Zhu H; Lai YS; Li Y; Blum RH; Kaufman DS Stem Cells; 2018 Feb; 36(2):134-145. PubMed ID: 29235195 [TBL] [Abstract][Full Text] [Related]
43. Development of an induced pluripotent stem cell-specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products. Chung L; Cogburn LA; Sui L; Dashnau JL Cytotherapy; 2022 Jul; 24(7):733-741. PubMed ID: 35461759 [TBL] [Abstract][Full Text] [Related]
44. Molecular and functional resemblance of differentiated cells derived from isogenic human iPSCs and SCNT-derived ESCs. Zhao MT; Chen H; Liu Q; Shao NY; Sayed N; Wo HT; Zhang JZ; Ong SG; Liu C; Kim Y; Yang H; Chour T; Ma H; Gutierrez NM; Karakikes I; Mitalipov S; Snyder MP; Wu JC Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11111-E11120. PubMed ID: 29203658 [TBL] [Abstract][Full Text] [Related]
45. A novel myeloid-like NK cell progenitor in human umbilical cord blood. Perez SA; Sotiropoulou PA; Gkika DG; Mahaira LG; Niarchos DK; Gritzapis AD; Kavalakis YG; Antsaklis AI; Baxevanis CN; Papamichail M Blood; 2003 May; 101(9):3444-50. PubMed ID: 12506032 [TBL] [Abstract][Full Text] [Related]
46. Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity. Flahou C; Morishima T; Takizawa H; Sugimoto N Front Immunol; 2021; 12():662360. PubMed ID: 33897711 [TBL] [Abstract][Full Text] [Related]
47. A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation. Vasu S; Berg M; Davidson-Moncada J; Tian X; Cullis H; Childs RW Cytotherapy; 2015 Nov; 17(11):1582-93. PubMed ID: 26432560 [TBL] [Abstract][Full Text] [Related]
48. Hematopoietic and nature killer cell development from human pluripotent stem cells. Ni Z; Knorr DA; Kaufman DS Methods Mol Biol; 2013; 1029():33-41. PubMed ID: 23756940 [TBL] [Abstract][Full Text] [Related]
49. Temporal Expression of Transcription Factor Jung J; Chang Y; Jin G; Lian X; Bao X ACS Synth Biol; 2022 Jun; 11(6):2001-2008. PubMed ID: 35608547 [TBL] [Abstract][Full Text] [Related]
50. Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy. Zhu H; Kaufman DS Blood Sci; 2019 Aug; 1(1):4-11. PubMed ID: 35402797 [TBL] [Abstract][Full Text] [Related]
51. Culture conditions affect cardiac differentiation potential of human pluripotent stem cells. Ojala M; Rajala K; Pekkanen-Mattila M; Miettinen M; Huhtala H; Aalto-Setälä K PLoS One; 2012; 7(10):e48659. PubMed ID: 23119085 [TBL] [Abstract][Full Text] [Related]
53. Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions. Arias J; Yu J; Varshney M; Inzunza J; Nalvarte I Stem Cells Transl Med; 2021 Jul; 10(7):987-995. PubMed ID: 33634954 [TBL] [Abstract][Full Text] [Related]
54. PROTAC-mediated vimentin degradation promotes terminal erythroid differentiation of pluripotent stem cells. Yan H; Zang R; Cui T; Liu Y; Zhang B; Zhao L; Li H; Zhou J; Wang H; Zeng Q; Xu L; Zhou Y; Pei X; Xi J; Yue W Stem Cell Res Ther; 2024 Sep; 15(1):310. PubMed ID: 39294765 [TBL] [Abstract][Full Text] [Related]
55. Characterization of developmental pathway of natural killer cells from embryonic stem cells in vitro. Tabatabaei-Zavareh N; Vlasova A; Greenwood CP; Takei F PLoS One; 2007 Feb; 2(2):e232. PubMed ID: 17311098 [TBL] [Abstract][Full Text] [Related]
56. Cancer therapy with major histocompatibility complex-deficient and interferon β-producing myeloid cells derived from allogeneic embryonic stem cells. Umemoto S; Haruta M; Sakisaka M; Ikeda T; Tsukamoto H; Komohara Y; Takeya M; Nishimura Y; Senju S Cancer Sci; 2019 Oct; 110(10):3027-3037. PubMed ID: 31348591 [TBL] [Abstract][Full Text] [Related]
57. RetSat stabilizes mitotic chromosome segregation in pluripotent stem cells. Cai W; Yao X; Liu G; Liu X; Zhao B; Shi P Cell Mol Life Sci; 2024 Aug; 81(1):366. PubMed ID: 39172275 [TBL] [Abstract][Full Text] [Related]
58. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Mrózek E; Anderson P; Caligiuri MA Blood; 1996 Apr; 87(7):2632-40. PubMed ID: 8639878 [TBL] [Abstract][Full Text] [Related]
59. Episomal vector reprogramming of human umbilical cord blood natural killer cells to an induced pluripotent stem cell line MUSIi013-A. Klaihmon P; Luanpitpong S; Lorthongpanich C; Laowtammathron C; Waeteekul S; Terbto P; Issaragrisil S Stem Cell Res; 2021 Aug; 55():102472. PubMed ID: 34311438 [TBL] [Abstract][Full Text] [Related]
60. Preferential Hematopoietic Differentiation in Induced Pluripotent Stem Cells Derived From Human Umbilical Cord Arterial Endothelial Cells. Pei H; Li H; Xu L; Zhang B; Zhang H; Jia Y; Liang L; Xie X; Fan Z; Yang Z; Wang X; Song F; He L; Yue W; Pei X Arterioscler Thromb Vasc Biol; 2023 May; 43(5):697-712. PubMed ID: 36951064 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]